Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SUPN 
Supernus Pharmaceuticals Inc (SUPN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: SUPN (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $60.5
1 Year Target Price $60.5
| 2 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.85% | Avg. Invested days 57 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.70B USD | Price to earnings Ratio - | 1Y Target Price 60.5 |
Price to earnings Ratio - | 1Y Target Price 60.5 | ||
Volume (30-day avg) 5 | Beta 0.72 | 52 Weeks Range 29.16 - 57.65 | Updated Date 12/8/2025 |
52 Weeks Range 29.16 - 57.65 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -2.81% | Operating Margin (TTM) 4.41% |
Management Effectiveness
Return on Assets (TTM) 1.52% | Return on Equity (TTM) -1.86% |
Valuation
Trailing PE - | Forward PE 20.16 | Enterprise Value 2380313508 | Price to Sales(TTM) 3.97 |
Enterprise Value 2380313508 | Price to Sales(TTM) 3.97 | ||
Enterprise Value to Revenue 3.49 | Enterprise Value to EBITDA 30.21 | Shares Outstanding 57339350 | Shares Floating 54816419 |
Shares Outstanding 57339350 | Shares Floating 54816419 | ||
Percent Insiders 4.26 | Percent Institutions 104.19 |
Upturn AI SWOT
Supernus Pharmaceuticals Inc
Company Overview
History and Background
Supernus Pharmaceuticals, Inc. was founded in 2005 and is a biopharmaceutical company focused on developing and commercializing products for CNS (central nervous system) disorders. Key milestones include the FDA approval and launch of its first two products, Oxtellar XR and Trokendi XR, for epilepsy. The company has since expanded its pipeline and product portfolio through internal development and strategic acquisitions.
Core Business Areas
- CNS Therapeutics: Development and commercialization of prescription pharmaceuticals for neurological and psychiatric conditions, primarily focusing on epilepsy and ADHD.
Leadership and Structure
Supernus Pharmaceuticals is led by a management team with extensive experience in the pharmaceutical industry. The company operates with a lean structure, focusing on research and development, regulatory affairs, and commercialization of its niche CNS products.
Top Products and Market Share
Key Offerings
- Trokendi XR (topiramate extended-release): A once-daily oral formulation of topiramate for the treatment of epilepsy and migraine prevention. Competitors include various generic topiramate formulations and other anti-epileptic drugs like Lamictal XR (lamotrigine), Keppra (levetiracetam), and Zonegran (zonisamide). Market share data is proprietary but it holds a significant position within its niche for epilepsy treatment.
- Oxtellar XR (oxcarbazepine extended-release): A once-daily oral formulation of oxcarbazepine for the treatment of epilepsy. Competitors include immediate-release oxcarbazepine (Trileptal) and other anti-epileptic drugs. Similar to Trokendi XR, it commands a notable share in its specific treatment areas.
- Qelbree (viloxazine extended-release): A novel, non-stimulant once-daily oral capsule for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric and adult patients. Competitors include stimulant medications like Adderall XR (mixed amphetamine salts), Ritalin LA (methylphenidate hydrochloride), and other non-stimulant options like Strattera (atomoxetine).
- Myalept (metreleptin): A leptin replacement therapy for patients with generalized lipodystrophy and partial lipodystrophy. This is a very niche product with limited direct competitors. The primary competitor might be supportive care or off-label treatments for the metabolic complications of lipodystrophy.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the CNS therapeutic area, is characterized by high R&D costs, strict regulatory oversight, long development cycles, and patent cliffs. There is continuous demand for novel treatments for neurological and psychiatric disorders, driven by an aging population and increasing awareness of mental health conditions.
Positioning
Supernus Pharmaceuticals is positioned as a specialist company in the CNS market, focusing on developing and commercializing differentiated products for underserved patient populations. Its competitive advantages include its expertise in developing extended-release formulations, strong intellectual property protection, and a targeted commercial strategy.
Total Addressable Market (TAM)
The TAM for CNS disorders, including epilepsy, ADHD, and rare metabolic diseases, is substantial and continues to grow. For epilepsy alone, the global market is estimated to be in the tens of billions of dollars. Supernus addresses a significant portion of this TAM with its approved products and is well-positioned within its niche areas.
Upturn SWOT Analysis
Strengths
- Established portfolio of approved CNS products with strong market positions in their respective niches.
- Expertise in developing extended-release drug formulations.
- Growing product pipeline with potential for future revenue streams.
- Strong intellectual property protection for key products.
- Experienced management team with a track record in the pharmaceutical industry.
Weaknesses
- Reliance on a limited number of products for revenue.
- Vulnerability to generic competition once patents expire.
- High cost of drug development and clinical trials.
- Limited diversification across therapeutic areas.
- Potential challenges in launching and gaining market share for newer products against established competitors.
Opportunities
- Expansion of existing product indications and patient populations.
- Acquisition of promising late-stage clinical assets or approved products.
- Partnerships and collaborations to advance pipeline candidates.
- Growth in emerging markets.
- Development of novel delivery systems for existing or new drugs.
Threats
- Increased competition from generic manufacturers.
- Regulatory hurdles and delays in drug approvals.
- Pricing pressures from payers and governments.
- Adverse clinical trial outcomes for pipeline candidates.
- Technological advancements by competitors leading to superior treatments.
Competitors and Market Share
Key Competitors
- Jazz Pharmaceuticals plc (JAZZ)
- Lundbeck (LUN)
- Takeda Pharmaceutical Company Limited (TAK)
- Pfizer Inc. (PFE)
- Novartis AG (NVS)
- Johnson & Johnson (JNJ)
Competitive Landscape
Supernus's advantage lies in its specialized focus on CNS disorders and its ability to develop differentiated formulations that offer improved patient compliance or efficacy. However, it faces intense competition from larger, more diversified pharmaceutical companies with extensive R&D budgets, established distribution networks, and broad product portfolios. Smaller, specialized companies also pose a threat by developing innovative treatments within specific CNS niches.
Major Acquisitions
Santhera Pharmaceuticals' US rights to AGAMREEu2122 (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD)
- Year: 2023
- Acquisition Price (USD millions): 40
- Strategic Rationale: To expand its rare disease portfolio and leverage its commercial infrastructure for a new therapeutic area with significant unmet need.
Newron Pharmaceuticals' U.S. rights to Safinamide (Exservan)
- Year: 2022
- Acquisition Price (USD millions): 30
- Strategic Rationale: To enhance its neurology franchise and add a complementary product for Parkinson's disease, leveraging its existing commercial expertise.
Growth Trajectory and Initiatives
Historical Growth: Supernus has demonstrated consistent historical revenue growth, largely propelled by the commercial success of Trokendi XR and Oxtellar XR, and more recently, Qelbree. The company has successfully navigated the transition from an R&D-stage company to a commercial-stage biopharmaceutical entity.
Future Projections: Analyst estimates suggest continued revenue growth for Supernus, driven by the expansion of its product portfolio and potential new approvals. The company is expected to leverage its existing infrastructure and market expertise to drive future sales.
Recent Initiatives: Recent initiatives include the successful launch of Qelbree for ADHD, ongoing clinical trials for pipeline assets, and strategic evaluations for potential business development opportunities, including acquisitions or licensing agreements.
Summary
Supernus Pharmaceuticals is a well-positioned CNS-focused biopharmaceutical company with a solid portfolio of approved products and a history of consistent growth. Its strengths lie in its specialized expertise and differentiated formulations, though it faces threats from generic competition and larger, more resource-rich competitors. Recent acquisitions indicate a strategic move to diversify its pipeline and expand into rare diseases, which could drive future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Supernus Pharmaceuticals Inc. Investor Relations Filings (SEC filings)
- Industry Analyst Reports
- Financial News Websites (e.g., Bloomberg, Reuters, Yahoo Finance)
- Pharmaceutical Market Research Databases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data is subject to change and may be subject to revisions. Market share figures are estimates and may vary depending on the source and methodology used.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Supernus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2012-05-01 | Founder, President, CEO, Secretary & Director Mr. Jack A. Khattar M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 674 | Website https://www.supernus.com |
Full time employees 674 | Website https://www.supernus.com | ||
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.